Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction.

Bayoumi E, Lam PH, Dooley DJ, Singh S, Faselis C, Morgan CJ, Patel S, Sheriff HM, Mohammed SF, Palant CE, Pitt B, Fonarow GC, Ahmed A.

Am J Med. 2019 Jan;132(1):71-80.e1. doi: 10.1016/j.amjmed.2018.09.011. Epub 2018 Sep 19.

PMID:
30240686
2.

Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate.

Lam PH, Gupta N, Dooley DJ, Singh S, Deedwania P, Zile MR, Bhatt DL, Morgan CJ, Pitt B, Fonarow GC, Ahmed A.

Am J Med. 2018 Dec;131(12):1473-1481. doi: 10.1016/j.amjmed.2018.07.008. Epub 2018 Aug 1.

PMID:
30076815
3.

Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers.

Lam PH, Bhyan P, Arundel C, Dooley DJ, Sheriff HM, Mohammed SF, Fonarow GC, Morgan CJ, Aronow WS, Allman RM, Waagstein F, Ahmed A.

Clin Cardiol. 2018 Mar;41(3):406-412. doi: 10.1002/clc.22889. Epub 2018 Mar 22.

4.

Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction.

Lam PH, Dooley DJ, Deedwania P, Singh SN, Bhatt DL, Morgan CJ, Butler J, Mohammed SF, Wu WC, Panjrath G, Zile MR, White M, Arundel C, Love TE, Blackman MR, Allman RM, Aronow WS, Anker SD, Fonarow GC, Ahmed A.

J Am Coll Cardiol. 2017 Oct 10;70(15):1861-1871. doi: 10.1016/j.jacc.2017.08.022.

5.

Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.

Lam PH, Dooley DJ, Fonarow GC, Butler J, Bhatt DL, Filippatos GS, Deedwania P, Forman DE, White M, Fletcher RD, Arundel C, Blackman MR, Adamopoulos C, Kanonidis IE, Aban IB, Patel K, Aronow WS, Allman RM, Anker SD, Pitt B, Ahmed A.

Eur J Heart Fail. 2018 Feb;20(2):359-369. doi: 10.1002/ejhf.937. Epub 2017 Oct 5.

6.

The Role of Positive Inotropic Drugs in the Treatment of Older Adults with Heart Failure and Reduced Ejection Fraction.

Dooley DJ, Lam PH, Ahmed A, Aronow WS.

Heart Fail Clin. 2017 Jul;13(3):527-534. doi: 10.1016/j.hfc.2017.02.008. Epub 2017 May 2. Review.

PMID:
28602370
7.

Corrigendum to "Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the cardiovascular health study" [Int. J. Cardiol. 235 (2017) 11-16].

Tsimploulis A, Sheriff HM, Lam PH, Dooley DJ, Anker MS, Papademetriou V, Fletcher RD, Faselis C, Fonarow GC, Deedwania P, White M, Valentova M, Blackman MR, Banach M, Morgan CJ, Alagiakrishnan K, Allman RM, Aronow WS, Anker SD, Ahmed A.

Int J Cardiol. 2017 Jul 1;238:181. doi: 10.1016/j.ijcard.2017.04.072. Epub 2017 May 6. No abstract available.

PMID:
28487149
8.

Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study.

Tsimploulis A, Sheriff HM, Lam PH, Dooley DJ, Anker MS, Papademetriou V, Fletcher RD, Faselis C, Fonarow GC, Deedwania P, White M, Valentova M, Blackman MR, Banach M, Morgan CJ, Alagiakrishnan K, Allman RM, Aronow WS, Anker SD, Ahmed A.

Int J Cardiol. 2017 May 15;235:11-16. doi: 10.1016/j.ijcard.2017.02.139. Epub 2017 Mar 1. Erratum in: Int J Cardiol. 2017 Jul 1;238:181.

PMID:
28291625
9.

Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.

Lam PH, Dooley DJ, Inampudi C, Arundel C, Fonarow GC, Butler J, Wu WC, Blackman MR, Anker MS, Deedwania P, White M, Prabhu SD, Morgan CJ, Love TE, Aronow WS, Allman RM, Ahmed A.

Int J Cardiol. 2017 Jan 15;227:462-466. doi: 10.1016/j.ijcard.2016.11.006. Epub 2016 Nov 4.

10.

A randomized pilot study on the effect of niacin on pulmonary arterial pressure.

McNamara MJ, Sayanlar JJ, Dooley DJ, Srichai MB, Taylor AJ.

Trials. 2015 Nov 21;16:530. doi: 10.1186/s13063-015-1013-6.

11.

Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ α2δ-1 subunit.

Quintero JE, Dooley DJ, Pomerleau F, Huettl P, Gerhardt GA.

J Pharmacol Exp Ther. 2011 Jul;338(1):240-5. doi: 10.1124/jpet.110.178384. Epub 2011 Apr 4.

12.

Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes.

Mantovani M, Dooley DJ, Weyerbrock A, Jackisch R, Feuerstein TJ.

Br J Pharmacol. 2009 Dec;158(7):1848-56. doi: 10.1111/j.1476-5381.2009.00478.x.

13.

Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin.

Brawek B, Löffler M, Dooley DJ, Weyerbrock A, Feuerstein TJ.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):301-7. Epub 2007 Dec 12.

PMID:
18074120
14.

Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission.

Dooley DJ, Taylor CP, Donevan S, Feltner D.

Trends Pharmacol Sci. 2007 Feb;28(2):75-82. Epub 2007 Jan 10. Review. Erratum in: Trends Pharmacol Sci. 2007 Apr;28(4):151.

PMID:
17222465
15.

Carboxylate bioisosteres of gabapentin.

Burgos-Lepley CE, Thompson LR, Kneen CO, Osborne SA, Bryans JS, Capiris T, Suman-Chauhan N, Dooley DJ, Donovan CM, Field MJ, Vartanian MG, Kinsora JJ, Lotarski SM, El-Kattan A, Walters K, Cherukury M, Taylor CP, Wustrow DJ, Schwarz JB.

Bioorg Med Chem Lett. 2006 May 1;16(9):2333-6. Epub 2005 Jun 8.

PMID:
15946842
16.

Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro.

Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS.

Eur J Neurosci. 2004 Sep;20(6):1566-76.

PMID:
15355323
18.

Comparison of the ORL1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices.

Rominger A, Förster S, Zentner J, Dooley DJ, McKnight AT, Feuerstein TJ, Jackisch R, Vlaskovska M.

Br J Pharmacol. 2002 Feb;135(3):800-6.

19.

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.

Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Göthert M.

Neuropharmacology. 2002 Feb;42(2):229-36.

PMID:
11804619
20.

Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin: involvement of KATP channels.

Freiman TM, Kukolja J, Heinemeyer J, Eckhardt K, Aranda H, Rominger A, Dooley DJ, Zentner J, Feuerstein TJ.

Naunyn Schmiedebergs Arch Pharmacol. 2001 May;363(5):537-42.

PMID:
11383714
21.

Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin.

Dooley DJ, Donovan CM, Pugsley TA.

J Pharmacol Exp Ther. 2000 Dec;295(3):1086-93.

PMID:
11082444
22.

(S)-4-Methyl-2-(methylamino)pentanoic acid [4, 4-bis(4-fluorophenyl)butyl]amide hydrochloride, a novel calcium channel antagonist, is efficacious in several animal models of pain.

Song Y, Bowersox SS, Connor DT, Dooley DJ, Lotarski SM, Malone T, Miljanich G, Millerman E, Rafferty MF, Rock D, Roth BD, Schmidt J, Stoehr S, Szoke BG, Taylor C, Vartanian M, Wang YX.

J Med Chem. 2000 Sep 21;43(19):3474-7. No abstract available.

PMID:
11000000
23.

Modulation of K(+)-induced synaptosomal calcium influx by gabapentin.

Meder WP, Dooley DJ.

Brain Res. 2000 Sep 1;875(1-2):157-9.

PMID:
10967310
24.
25.

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin.

Dooley DJ, Mieske CA, Borosky SA.

Neurosci Lett. 2000 Feb 18;280(2):107-10.

PMID:
10686389
26.

Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers.

Hu LY, Ryder TR, Rafferty MF, Dooley DJ, Geer JJ, Lotarski SM, Miljanich GP, Millerman E, Rock DM, Stoehr SJ, Szoke BG, Taylor CP, Vartanian MG.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2151-6.

PMID:
10465535
27.

Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas.

Newcomb R, Szoke B, Palma A, Wang G, Chen Xh, Hopkins W, Cong R, Miller J, Urge L, Tarczy-Hornoch K, Loo JA, Dooley DJ, Nadasdi L, Tsien RW, Lemos J, Miljanich G.

Biochemistry. 1998 Nov 3;37(44):15353-62.

PMID:
9799496
28.

Reduction of 3,4-diaminopyridine-induced biogenic amine synthesis and release in rat brain by gabapentin.

Pugsley TA, Whetzel SZ, Dooley DJ.

Psychopharmacology (Berl). 1998 May;137(1):74-80.

PMID:
9631959
29.

Assessment of endothelin receptor subtype-mediated increases of [Ca2+]i in distinct rat cell types using fluorimetric imaging.

Dooley DJ, Geer JJ, Haleen SJ, Probert AW, Welch KM.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S192-5.

PMID:
9595435
30.

A summary of mechanistic hypotheses of gabapentin pharmacology.

Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L.

Epilepsy Res. 1998 Feb;29(3):233-49. Review.

PMID:
9551785
31.

P-type Ca2+ channels trigger stimulus-evoked [3H]acetylcholine release from mammalian motor endplates.

Wessler I, Dooley DJ, Lohr B.

Eur J Pharmacol. 1995 May 4;278(1):83-6.

PMID:
7664817
32.

Conodipine-M, a novel phospholipase A2 isolated from the venom of the marine snail Conus magus.

McIntosh JM, Ghomashchi F, Gelb MH, Dooley DJ, Stoehr SJ, Giordani AB, Naisbitt SR, Olivera BM.

J Biol Chem. 1995 Feb 24;270(8):3518-26.

33.

Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers.

Roufos I, Hays SJ, Dooley DJ, Schwarz RD, Campbell GW, Probert AW Jr.

J Med Chem. 1994 Jan 21;37(2):268-74.

PMID:
8295214
34.

Characteristics of [125I]omega-conotoxin MVIIA binding to rat neocortical membranes.

Stoehr SJ, Dooley DJ.

Neurosci Lett. 1993 Oct 14;161(1):113-6.

PMID:
8255536
37.

Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.

Dooley DJ, Klamt I.

Psychopharmacology (Berl). 1993;112(4):452-4.

PMID:
7871056
38.

Bradykinin and angiotensin II analogs containing a conformationally constrained proline analog.

Juvvadi P, Dooley DJ, Humblet CC, Lu GH, Lunney EA, Panek RL, Skeean R, Marshall GR.

Int J Pept Protein Res. 1992 Sep-Oct;40(3-4):163-70.

PMID:
1335995
39.
40.
41.

Aging and endothelin-1 induced vascular contractions.

Weinheimer G, Dooley DJ, Cazzonelli M, Osswald H.

Experientia. 1990 Oct 15;46(10):1008-9.

PMID:
2226712
43.

Inhibition of norepinephrine and acetylcholine release from human neocortex by omega-conotoxin GVIA.

Feuerstein TJ, Dooley DJ, Seeger W.

J Pharmacol Exp Ther. 1990 Feb;252(2):778-85.

PMID:
2156061
44.
45.
46.

Omega-conotoxin GVIA and pharmacological modulation of hippocampal noradrenaline release.

Dooley DJ, Lupp A, Hertting G, Osswald H.

Eur J Pharmacol. 1988 Mar 29;148(2):261-7.

PMID:
3378575
47.

Inhibition of central neurotransmitter release by omega-conotoxin GVIA, a peptide modulator of the N-type voltage-sensitive calcium channel.

Dooley DJ, Lupp A, Hertting G.

Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct;336(4):467-70.

PMID:
2448660
49.

Characterization of the dihydropyridine binding sites of rat neocortical synaptosomes and microvessels.

Dooley DJ, Mählmann H, Brenner O, Osswald H.

J Neurochem. 1987 Sep;49(3):900-4.

PMID:
3039058
50.

Quantitative assessment of central beta 1- and beta 2-adrenoceptor regulation using CGP 20712 A.

Dooley DJ, Bittiger H.

J Pharmacol Methods. 1987 Sep;18(2):131-6.

PMID:
2887701

Supplemental Content

Loading ...
Support Center